A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.

Kelesitse Phiri,Jesper Hallas,Marie Linder,Andrea V. Margulis,Brandon T. Suehs,Alejandro Arana,Shahram Bahmanyar,Veena Hoffman,Cheryl Enger,Libby Horter,Ingvild Odsbu,Morten Olesen,Susana Perez-Gutthann,Nina Sahlertz Kristiansen,Kwame Appenteng,Stefan de Vogel,John D. Seeger

A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.

2021

Kelesitse Phiri
Jesper Hallas
Marie Linder
Andrea V. Margulis
Brandon T. Suehs
Alejandro Arana
Shahram Bahmanyar
Veena Hoffman
Cheryl Enger
Libby Horter
Ingvild Odsbu
Morten Olesen
Susana Perez-Gutthann
Nina Sahlertz Kristiansen
Kwame Appenteng
Stefan de Vogel
John D. Seeger

This post-authorization safety study (EU PAS Register Number: EUPAS16088) was designed to compare the incidence of cancer outcomes in patients treated with mirabegron versus antimuscarinic medicati...

Keywords:

Urology
Treatments for overactive bladder
Cancer
Urinary bladder
Medicine
in patient
Mirabegron

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations